Luhmann Janet, Hurt Sarah, Shootman Mario, Kennedy Robert
Division of Emergency Medicine, Department of Pediatrics, St Louis Children's Hospital, Washington University School of Medicine, St Louis, Missouri 63110-1077, USA.
Pediatrics. 2004 Mar;113(3 Pt 1):e217-20. doi: 10.1542/peds.113.3.e217.
Peripheral intravenous catheter (PIV) insertion is a common, painful experience for many children in the pediatric emergency department. Although local anesthetics such as injected buffered lidocaine have been shown to be effective at reducing pain and anxiety associated with PIV insertion, they are not routinely used. ELA-Max, a topical local anesthetic, has the advantage of needle-free administration but has not been compared with buffered lidocaine for PIV insertion.
To compare the reduction of pain and anxiety during PIV insertion provided by subcutaneous buffered 1% lidocaine or topical ELA-Max in children.
A randomized trial in children 4 to 17 years old undergoing PIV insertion with 22-gauge catheters was conducted. Children received either buffered lidocaine or ELA-Max. Buffered lidocaine was administered by using 30-gauge needles to inject 0.1 to 0.2 mL subcutaneously just before PIV insertion. ELA-Max was applied to the skin and occluded with Tegaderm 30 minutes before PIV insertion. Self-reported Visual Analog Scale (VAS) questionnaires (rating on a scale of 1-10; 1 = no pain, anxiety) were completed by patients and their parents before PIV insertion to assess baseline perceptions about pain and anxiety associated with PIV insertion and immediately after PIV insertion to assess pain and anxiety associated with the experience. After PIV insertion, the nurse who inserted the PIV also completed a VAS questionnaire assessing technical difficulty and satisfaction with the local anesthesia. A blinded observer also completed a VAS questionnaire to assess pain and anxiety associated with the PIV insertion. Data were analyzed by using chi2 and t tests.
Sixty-nine subjects were enrolled, and questionnaires were competed by all (mean age: 12.1 +/- 4.5 years; 61% female). There were no differences for buffered lidocaine and ELA-Max groups in age, gender, race, prior IV experience, or baseline pain and anxiety. There were no significant differences between buffered lidocaine and ELA-Max in mean pain and anxiety after PIV insertion by patient, parent, and blinded observer ratings. Nurse ratings of technical difficulty, number of PIV-insertion attempts, and satisfaction with local anesthesia also were not significantly different for buffered lidocaine and ELA-Max groups.
ELA-Max provided similar pain and anxiety reduction during PIV insertion in children compared with injected buffered lidocaine. Technical difficulty and satisfaction by nurses inserting the PIV also were similar.
外周静脉导管(PIV)插入术对许多儿科急诊科的儿童来说是一种常见的痛苦经历。尽管局部麻醉剂如注射用缓冲利多卡因已被证明能有效减轻与PIV插入相关的疼痛和焦虑,但它们并未被常规使用。ELA-Max是一种局部外用麻醉剂,具有无需注射的优点,但尚未与缓冲利多卡因在PIV插入术中进行比较。
比较皮下注射1%缓冲利多卡因或局部应用ELA-Max在儿童PIV插入术中减轻疼痛和焦虑的效果。
对4至17岁接受22号导管PIV插入术的儿童进行一项随机试验。儿童接受缓冲利多卡因或ELA-Max治疗。缓冲利多卡因在PIV插入术前使用30号针头皮下注射0.1至0.2 mL。ELA-Max在PIV插入术前30分钟涂抹于皮肤上并用德湿可贴膜覆盖。患者及其父母在PIV插入术前完成自我报告的视觉模拟量表(VAS)问卷(评分范围为1至10;1 = 无疼痛、焦虑),以评估对与PIV插入相关的疼痛和焦虑的基线认知,并在PIV插入术后立即完成问卷以评估与该经历相关的疼痛和焦虑。PIV插入术后,插入PIV的护士也完成一份VAS问卷,评估技术难度和对局部麻醉的满意度。一名盲法观察者也完成一份VAS问卷,以评估与PIV插入相关的疼痛和焦虑。数据采用卡方检验和t检验进行分析。
纳入69名受试者,所有人均完成问卷(平均年龄:12.1±4.5岁;61%为女性)。缓冲利多卡因组和ELA-Max组在年龄、性别、种族、既往静脉穿刺经验或基线疼痛和焦虑方面无差异。在患者、父母和盲法观察者的评分中,缓冲利多卡因组和ELA-Max组在PIV插入术后的平均疼痛和焦虑方面无显著差异。缓冲利多卡因组和ELA-Max组在护士对技术难度、PIV插入尝试次数以及对局部麻醉的满意度评分方面也无显著差异。
与注射用缓冲利多卡因相比,ELA-Max在儿童PIV插入术中减轻疼痛和焦虑的效果相似。插入PIV的护士的技术难度和满意度也相似。